Showing results (221-230 of 353) with videos related to
Sort By:
Pageof 36
Regulatory Peptides|May 28, 2011
Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized sclerodermaThilo Gambichler, Marina Skrygan, Alexandra Anna Labanski, et al.Journal of the American Academy of Dermatology|October 20, 2009
Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic optionsGisela Schieren, Nikolaus Wirtz, Peter Altmeyer, et al.Dermatology and Therapy|March 9, 2023
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled TrialAlexa B Kimball, Errol P Prens, Thierry Passeron, et al.Life (Basel, Switzerland)|October 27, 2022
Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBestNatalia Kirsten, Frenz Ohm, Kathrin Gehrdau, et al.Archives of Dermatological Research|October 10, 2002
Apoptosis of human dermal endothelial cells as a potential side effect following therapeutic administration of UVA1 irradiation: preliminary resultsFrank Breuckmann, Gregor von Kobyletzki, Annelies Avermaete, et al.Journal of the American Academy of Dermatology|January 31, 2006
Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patientsAnna Sommer, Thilo Gambichler, Martina Bacharach-Buhles, et al.American Journal of Clinical Dermatology|June 25, 2008
Acute kidney injury in a patient with melanuria, diffuse melanosis, and metastatic malignant melanomaThilo Gambichler, Markus Stücker, Katja Kerner, et al.Acta Dermato-Venereologica|March 6, 2025
Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HSNatalia Kirsten, Matthias Augustin, Christine Blome, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 1, 2010
Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesionsGisela Schieren, Thilo Gambichler, Marina Skrygan, et al.Archives of Dermatology|September 20, 2006
1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled studyAlexander Kreuter, Anna Sommer, Julia Hyun, et al.Pageof 36